Meniscusprothesis ATRO Medical receives FDA breakthrough Designation

03 / 02 / 20

Knee ostheoarthritis is one of the most important causes of invalidity in Europe and the US. The Trammpolin meniscusprothesis is an implant aimed at reducing knee pain and restoring mobility. Now this innovation is taking part in the Breakthrough Device Designation-program of FDA.

Meniscusprothesis ATRO Medical receives FDA breakthrough Designation

In the media
03 / 02 / 20

Knee ostheoarthritis is one of the most important causes of invalidity in Europe and the US. The Trammpolin meniscusprothesis is an implant aimed at reducing knee pain and restoring mobility. Now this innovation is taking part in the Breakthrough Device Designation-program of FDA.

Jan Hunik, CEO of ATRO Medical, states: “We’re looking forward to the intensified collaboration with FDA and are convinced that this will speed up our access to the US market.”

 

Read the full version of this article on the website of Radboudumc.